Drugs / Ularitide

Trials 4 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00487799 congestive heart failure Facet Biotech Withdrawn No outcome recorded
Phase 22 trials
Phase 2 NCT04311489 Aug 2020 → Nov 2022 cirrhosis of liver University of Aarhus Terminated No outcome recorded
Phase 2 NCT00390624 Jul 2003 → Dec 2006 acute kidney injury, impaired renal function disease Rocky Mountain Cancer Centers Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01661634 Jul 2012 → Nov 2015 heart failure Cardiorentis Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as ULARITIDE “URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)” NCT00390624
3

NCT00487799

NCT01661634

NCT04311489

Known as Ularitida ChEMBL registry synonym — accepted as the source's own label CHEMBL2103920
Known as Ularitide acetate ChEMBL registry synonym — accepted as the source's own label CHEMBL2103920
Known as Urodilatin “Ularitide (Urodilatin) Intravenous Infusion” NCT01661634
1

NCT00390624

Known as Urodilatin ularitide ChEMBL registry synonym — accepted as the source's own label CHEMBL2103920
Modality Peptide “URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)” NCT00390624
Modality Protein / enzyme biologic CHEMBL2103920
Route Intravenous “continuous intravenous (IV) ularitide infusion” NCT01661634